scPharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume26,807 shs
Average Volume85,369 shs
Market Capitalization$156.47 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

scPharmaceuticals logo

About scPharmaceuticals

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.30 out of 5 stars

Medical Sector

875th out of 2,096 stocks

Pharmaceutical Preparations Industry

421st out of 830 stocks

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

scPharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions

Is scPharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" scPharmaceuticals stock.
View analyst ratings for scPharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than scPharmaceuticals?

Wall Street analysts have given scPharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but scPharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is scPharmaceuticals' next earnings date?

scPharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for scPharmaceuticals

How were scPharmaceuticals' earnings last quarter?

scPharmaceuticals Inc. (NASDAQ:SCPH) issued its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04.
View scPharmaceuticals' earnings history

How has scPharmaceuticals' stock price been impacted by Coronavirus?

scPharmaceuticals' stock was trading at $7.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SCPH stock has decreased by 26.4% and is now trading at $5.72.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SCPH?

2 analysts have issued 12 month price targets for scPharmaceuticals' stock. Their forecasts range from $10.00 to $12.00. On average, they anticipate scPharmaceuticals' stock price to reach $11.00 in the next year. This suggests a possible upside of 92.3% from the stock's current price.
View analysts' price targets for scPharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are scPharmaceuticals' key executives?

scPharmaceuticals' management team includes the following people:
  • Mr. John H. Tucker, Pres, CEO, Principal Exec. Officer, Principal Financial Officer & Director (Age 58, Pay $780.46k)
  • Ms. Rachael Nokes, Sr. VP of Fin. & Principal Accounting Officer (Age 46, Pay $433.54k)
  • Katherine Taudvin, Director of Corp. Devel. & Investor Relations
  • Dr. John Mohr Pharm.D., Sr. VP of Clinical Devel. & Medical Affairs
  • Mr. Michael D. Hassman, Sr. VP of Technical Operations

Who are some of scPharmaceuticals' key competitors?

What other stocks do shareholders of scPharmaceuticals own?

When did scPharmaceuticals IPO?

(SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is scPharmaceuticals' stock symbol?

scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

Who are scPharmaceuticals' major shareholders?

scPharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.98%), Ikarian Capital LLC (4.78%), Goldman Sachs Group Inc. (2.37%), BlackRock Inc. (1.20%), Worth Venture Partners LLC (0.78%) and Renaissance Technologies LLC (0.70%). Company insiders that own scPharmaceuticals stock include Andrew J Schwab, John H Tucker and Ra Capital Management, LP.
View institutional ownership trends for scPharmaceuticals

Which major investors are selling scPharmaceuticals stock?

SCPH stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Ikarian Capital LLC, Renaissance Technologies LLC, and Northern Trust Corp.
View insider buying and selling activity for scPharmaceuticals
or view top insider-selling stocks.

Which major investors are buying scPharmaceuticals stock?

SCPH stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Worth Venture Partners LLC, Morgan Stanley, BlackRock Inc., Geode Capital Management LLC, and Barclays PLC. Company insiders that have bought scPharmaceuticals stock in the last two years include Andrew J Schwab, John H Tucker, and Ra Capital Management, LP.
View insider buying and selling activity for scPharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of scPharmaceuticals?

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is scPharmaceuticals' stock price today?

One share of SCPH stock can currently be purchased for approximately $5.72.

How much money does scPharmaceuticals make?

scPharmaceuticals has a market capitalization of $156.47 million. The company earns $-32,210,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.

How many employees does scPharmaceuticals have?

scPharmaceuticals employs 27 workers across the globe.

What is scPharmaceuticals' official website?

The official website for scPharmaceuticals is

Where are scPharmaceuticals' headquarters?

scPharmaceuticals is headquartered at 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830.

How can I contact scPharmaceuticals?

scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]

This page was last updated on 6/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.